In preclinical models, tumors with elevated HDAC7/Myc expression exhibit markedly enhanced sensitivity [72] to XPO1 inhibitors, compared to non-HDAC7+ SCLC, proposing HDAC as an essential biomarker for stratifying SCLC patients for XPO1-targeted therapy. Here, HDAC9 is linked to small cell lung carcinoma.